21 September 2023 - Dizal announced today that the China National Medical Products Administration has granted priority review status to golidocitinib, Dizal's investigational JAK1 only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma. 

In February 2022, golidocitinib received fast track designation from the US FDA for the same indication, making it the first and only innovative drug in China to receive this recognition for peripheral T-cell lymphoma.

Read Dizal Pharmaceutical press release